Qsymia Data by Patient Type

Qsymia can help you treat many of the patients you see in your practice1,2

Qsymia is the only once-daily combination pill proven to significantly reduce weight1-5

  • Qsymia was studied in 2 large trials supporting FDA approval that involved 3754 patients whose BMI was 30 kg/m2 or greater, or 27 kg/m2 or greater with 2 or more weight-related comorbidities such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg, phentermine 7.5 mg/topiramate 46 mg, or phentermine 15 mg/topiramate 92 mg. In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day. Your patients’ results may vary depending on their BMI, diet, activity, dose of Qsymia, and other factors1,2
  • In a subset analysis, patients with a BMI ≥30 kg/m2 taking the recommended dose of Qsymia (n=2076) lost an average of approximately 10% of their body weight, 4 inches off their waist, and 24 pounds after 1 year2

Qsymia can help you treat many of the patients you see in your practice1,2

Review the range of overweight and obese patient evaluted in clinical studies. Click on a patient type to view more data.

Comorbid BMI Range Difficult to Treat

Patient Type 1: Comorbid

Qsymia provides reliable efficacy for obese patients with comorbidities1,2

Absolute Weight Reduction After 1 Year in Patients With a Baseline BMI of 30 kg/m2 1,2


 
Statistical significance achieved (type 2 diabetes: P=.0115; hypertension: P<.0001; P values are from Fisher’s exact test).2 Qsymia is not indicated for the treatment of type 2 diabetes, hypertension, dyslipidemia, or depression.1

Back to top   Back to top

Patient Type 2: BMI Range

Qsymia helped patients successfully lose weight across a range of BMI1,2

Percentage of Weight Reduction by BMI After 1 Year1,2

Back to top   Back to top

Patient Type 3: Difficult to Treat

Diffcult-to-treat populations significantly reduced weight in clinical trials1,2

Absolute Weight Reduction Across Patient Segments With a BMI 30 kg/m2 After 1 Year1,2

 
*Qsymia is contraindicated for hyperthyroidism.1
General dose selection should be cautious, starting with lowest dose.1
LS=least squares.
§ P<.0001 vs placebo.

Qsymia has been proven effective in obese patients with metabolic challenges that cause weight gain, increased abdominal fat, and/or diffculty losing weight. Included in clinical studies were a variety of diffcult-to-treat patients such as those who were menopausal, postmenopausal, aged 50 years or older, or suffering from hypothyroidism.2,6-10

Back to top   Back to top

A new, special offer for your Qsymia patients

The new, Smart Changes Program is a comprehensive program that combines positive lifestyle changes with a prescription medication proven to help patients lose significant weight.

Smart Changes logo
  • THE QSYMIA “SAVE RIGHT FROM THE START” OFFER
  • A FREE, LIMITED, 3-MONTH SUBSCRIPTION TO
    The Mayo Clinic Diet
Learn More

Restrictions apply. See eligibility conditions for the savings offer and the Smart Changes Program on the Qsymia patient site.

This limited free-trial offer does not represent an actual or implied endorsement of Qsymia by Mayo Clinic or The Mayo Clinic Diet. Mayo Clinic has authorized VIVUS to distribute The Mayo Clinic Diet. Mayo Clinic does not endorse any non-Mayo products or services.

Qsymia is the only once-daily combination pill proven to significantly reduce weight1-5

Choose Qsymia as first-line choice for a range of overweight and obese patient types who need to achieve significant weight loss1-2

Review the Data